DexCom revenue and financials
$83.59Change from previous close: −3.81%Absolute change: −$3.32
In the fiscal year ended December 2025, DexCom reported revenue of $4.66B (+15.60% year over year). Net income was $836.3M, a net margin of 17.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +15.60%
- 2025 vs 2024
- Net income growth
- +45.14%
- 2025 vs 2024
- Net margin
- 17.9%
- 2024: 14.3%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total assets | 6,455 | 6,633 | 6,340 | 7,500 | 7,327 | — |
| Current assets | 4,087 | 4,332 | 4,033 | 5,220 | 5,030 | — |
| Cash and equivalents | 1,105 | 1,118 | 918 | 1,836 | 1,159 | — |
| Short-term investments | 842 | 1,297 | 1,081 | 1,486 | 1,770 | — |
| Receivables | 1,283 | 1,105 | 1,290 | 1,169 | 1,377 | — |
| Inventory | 726 | 694 | 629 | 604 | 571 | — |
| Net property, plant and equipment | 1,665 | 1,633 | 1,637 | 1,525 | 1,514 | — |
| Goodwill | 24.1 | 24.2 | 24.2 | 24.1 | 24.1 | — |
| Other intangible assets | 117 | 80.7 | 70.8 | 79.0 | 87.2 | — |
| Long-term investments | 210 | 220 | 218 | 217 | 116 | — |
| Current liabilities | 2,358 | 2,224 | 2,143 | 3,336 | 3,309 | — |
| Accounts payable | 424 | 394 | 344 | 452 | 472 | — |
| Long-term debt | 1,243 | 1,242 | 1,241 | 1,240 | 1,239 | — |
| Total debt | 1,398 | 1,385 | 1,390 | 2,576 | 2,579 | — |
| Total liabilities | 3,834 | 3,676 | 3,594 | 4,774 | 4,754 | — |
| Total equity (incl. minority) | 2,621 | 2,957 | 2,746 | 2,726 | 2,573 | — |
| Retained earnings | 2,883 | 2,633 | 2,434 | 2,167 | 1,883 | — |